Dr. Robert Levin, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 46
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 276
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
FL license ME44516
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Medical Specialists of the Palm Beaches Inc (119 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 276
- Services billed
- 2,370
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 711 | 279 |
| Advance care planning, first 30 minutes | 234 | 234 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 191 | 191 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 173 | 163 |
| Annual depression screening, 5 to 15 minutes | 81 | 81 |
| Established patient office or other outpatient visit, 20-29 minutes | 36 | 29 |
| Annual alcohol misuse screening, 5 to 15 minutes | 36 | 36 |
| Transitional care management services for problem of high complexity | 19 | 15 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 12 payments worth $476 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $259 |
|---|---|
| Lilly USA, LLC | $60.13 |
| Amgen Inc. | $57.55 |
| Pfizer Inc. | $29.91 |
| Novo Nordisk Inc | $27.94 |
| Scilex Pharmaceuticals Inc. | $21.46 |
| Abiomed | $19.96 |
| Food and Beverage | $476 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $123,138 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1)
E.r. Squibb & Sons, L.l.c. - A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With S…
Novartis Pharmaceuticals Corporation - A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
UCB SA · Recruiting · NCT06617325
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.